| 8.09 0.16 (2.02%) | 02-02 10:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.74 | 1-year : | 11.38 |
| Resists | First : | 8.34 | Second : | 9.74 |
| Pivot price | 7.88  |
|||
| Supports | First : | 7.6 | Second : | 7.13 |
| MAs | MA(5) : | 7.88 |
MA(20) : | 7.85 |
| MA(100) : | 7.28 |
MA(250) : | 7.58 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 44.9 |
D(3) : | 40.6 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 11.25 | Low : | 5.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BVS ] has closed below upper band by 31.8%. Bollinger Bands are 41.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.95 - 7.98 | 7.98 - 8.01 |
| Low: | 7.58 - 7.62 | 7.62 - 7.65 |
| Close: | 7.87 - 7.93 | 7.93 - 7.98 |
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Thu, 22 Jan 2026
Bioventus (NYSE:BVS) Trading Up 3.8% - Still a Buy? - MarketBeat
Wed, 14 Jan 2026
Bioventus (NASDAQ:BVS) Stock Price Down 0.6% - Should You Sell? - MarketBeat
Wed, 14 Jan 2026
BVS: Transformation and innovation drive strong growth, high margins, and expanding global opportunities - TradingView
Wed, 14 Jan 2026
Institutional investors own a significant stake of 36% in Bioventus Inc. (NASDAQ:BVS) - Yahoo Finance
Sat, 10 Jan 2026
Recent uptick might appease Bioventus Inc. (NASDAQ:BVS) institutional owners after losing 13% over the past year - simplywall.st
Tue, 02 Dec 2025
Bioventus: A New Start (NASDAQ:BVS) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 67 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 11.7 (%) |
| Held by Institutions | 74.4 (%) |
| Shares Short | 1,690 (K) |
| Shares Short P.Month | 1,780 (K) |
| EPS | 0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.48 |
| Profit Margin | 1.7 % |
| Operating Margin | 8.1 % |
| Return on Assets (ttm) | 4.1 % |
| Return on Equity (ttm) | 6.3 % |
| Qtrly Rev. Growth | -0.3 % |
| Gross Profit (p.s.) | 5.7 |
| Sales Per Share | 8.41 |
| EBITDA (p.s.) | 0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 56 (M) |
| Levered Free Cash Flow | 34 (M) |
| PE Ratio | 49.87 |
| PEG Ratio | 0 |
| Price to Book value | 3.21 |
| Price to Sales | 0.94 |
| Price to Cash Flow | 9.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|